DOCSLIB.ORG

Serms in the Prevention and Treatment of Postmenopausal Osteoporosis: an Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serms in the Prevention and Treatment of Postmenopausal Osteoporosis: an Update review SERMs in the prevention and treatment of postmenopausal osteoporosis: an update SERMs na prevenção e no tratamento da osteoporose pós-menopausa: uma atualização Jaime Kulak Júnior1, Carolina Aguiar Moreira Kulak2, Hugh S. Taylor3 SUMMARY 1 Serviço de Tocoginecologia, Selective estrogen receptor modulators (SERMs) have the ability to bind the estrogen receptor Hospital de Clínicas, Universidade Federal do Paraná (UFPR), (ER) and are known to confer ER agonist or antagonist effects depending on the target tissue. Curitiba, PR, Brasil A number of newer SERMs, including bazedoxifene, lasofoxifene and ospemifene, are currently 2 Serviço de Endocrinologia e under clinical development for the prevention and treatment of postmenopausal osteoporosis Metabologia (SEMPR), Hospital de Clínicas, UFPR, Curitiba, PR, Brasil and for other indications. Although the possibility of developing a single agent that has all of 3 Departamento de Obstetrícia, the desired characteristics of an ideal SERM seems to be unlikely, progress in the clinical deve- Ginecologia e Ciências de lopment of SERMs targeted to the ER suggests that these newer compounds may have attribu- Reprodução, Yale University School of Medicine, New tes that represent an improvement relative to existing SERMs. A new approach to menopausal Haven, CT, United States therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. Further investigation will help to clarify relative benefits/risks of no- vel SERMs in development within specific indications. Arq Bras Endocrinol Metab. 2010;54(2):200-5 Keywords Selective estrogen receptor modulator (SERM); menopause; estrogens; osteoporosis; tissue selective estrogen complex (TSEC) SUMÁRIO Correspondence to: Moduladores seletivos do receptor do estrogênio (SERMs) têm a habilidade de se ligar ao re- Jaime Kulak Júnior Rua General Carneiro, 180, ceptor de estrogênio (ER) e são conhecidos por conferir um efeito agonista ou antagonista 6º andar sobre o tecido-alvo. Um número de novos SERMs, incluindo bazedoxifeno, lasofoxifeno e os- 80060-150 − Curitiba, PR, Brasil [email protected] pemifeno, está atualmente em desenvolvimento clínico para prevenção e tratamento da os- teoporose pós-menopausa e para outras indicações. Embora a possibilidade de desenvolver um simples agente que tenha todas as características desejadas de um SERM ideal parece ser Received on Nov/30/2009 Accepted on Feb/9/2010 pouco provável, esses novos SERMs apresentam propriedades que indicam uma melhora em relação aos SERMs existentes. Uma nova opção terapêutica é o uso do complexo estrogênico do tecido seletivo ou a associação do SERM com estrogênios. Novos estudos ajudarão a ras- trear os riscos e benefícios dos novos SERMs em desenvolvimento dentro das suas indicações específicas. Arq Bras Endocrinol Metab. 2010;54(2):200-5 Descritores Moduladores específicos dos receptores de estrogênio (SERM); menopausa; estrogênio; osteoporose; complexo estrogênico do tecido seletivo (TSEC) INTRODUCTION agents for the management of postmenopausal osteo- ostmenopausal osteoporosis is an asymptomatic porosis may not be appropriate for all women. Selective Pskeletal disease that is often underdiagnosed and estrogen receptor modulator (SERM) refers to a struc- undertreated. Adequate intake of calcium and vitamin D turally diverse group of compounds that bind to the es- ABE&M todos os direitos reservados. os direitos ABE&M todos © is recommended as baseline therapy for osteoporosis trogen receptor (ER) and confer mixed functional ER Copyright prevention and treatment. Available pharmacological agonist or antagonist activity depending on the target 200 Arq Bras Endocrinol Metab. 2010;54/2 SERMs and osteoporosis an update tissue. Conceptually, an ideal SERM would have ER Table 1. Effects of SERMs Endometrial Vaginal agonist activity in tissues where mimicking the action of SERM Hot flushes estrogens is desirable (e.g., skeletal, cardiovascular, and stimulation maturation central nervous systems), and ER neutral or antagonist Tamoxifen Yes No ↑ activity in tissues estrogens have been shown to adverse- Raloxifene Yes No ↑ ly stimulate (e.g., breast and endometrium) (1). Despite Lasofoxifene Yes Yes ↑ the lack of an ideal SERM to date, a number of SER- Ospemifene Yes Yes - Ms have demonstrated a favorable benefit-risk balance Bazedoxifene No No ↑ within specific therapeutic indications. Newer SERMs are currently undergoing clinical investigation for the CURRENTLY AVAILABLE SERMS management of postmenopausal conditions associated with estrogen deficiency, particularly osteoporosis. This Tamoxifen update describes the most recent literature on SERMs Tamoxifen has a well known antiestrogen activity in the to evaluate their safety and efficacy on the treatment of breast and estrogen-like activity in the uterus (6), and is postmenopausal osteoporosis. It should be noted that recognized as a highly effective agent for the treatment the US Food and Drug Administration (FDA) recen- of ER-positive breast cancer. Tamoxifen has also been tly replaced the term “SERM” with “estrogen agonist/ shown to provide skeletal and cardioprotective bene- antagonist drug”; however, in this review, the term fits (7,8); however, endometrial safety concerns limit “SERM” will be used throughout the article. its use in the postmenopausal population with breast cancer. Tamoxifen is associated with an increased in- THE PROMISE OF SERMS cidence of venous thromboembolic events, vasomotor symptoms, and sometimes stroke (9,10). SERMs are known to bind to ERs with high affinity and to mediate transcriptional events (2). The prom- Raloxifene ise of SERMs lies in their ability to differentially act as ER agonists or antagonists depending on the target tis- Raloxifene is the only SERM approved worldwide for sue (3). The exact mechanisms by which SERMs exert the prevention and treatment of postmenopausal osteo- their tissue-specific actions are not totally understood, porosis and vertebral fractures and it is also indicated although evidence suggests that the balance of ER co- for the prevention of breast cancer in postmenopausal regulators and the cellular microenvironment interact women. In postmenopausal women with low or normal to determine the effect of a SERM on a given cell type bone mineral density (BMD), treatment with raloxi- (4). Microarray gene expression analysis has shown that fene 60 mg was shown to increase lumbar spine BMD different sets of genes are regulated through ERα ver- by 2.4% relative to placebo (P < 0.001) (11). The Mul- sus ERβ in response to estradiol and SERMs (2). The tiple Outcomes of Raloxifene Evaluation (MORE) trial wide-ranging effects of SERMs seem to be mediated found that treatment with raloxifene 60 and 120 mg/ by expression of the ER in different tissues, ER confor- day for 3 years significantly reduced vertebral fracture mation after binding of the ER ligand, and expression risk by 30% (relative risk, 0.7; 95% CI, 0.5-0.8) and and binding of the ER/ligand complex to coregulator 50% (relative risk, 0.5; 95% CI, 0.4-0.7) compared with proteins (1). SERMs are characterized by their complex placebo, respectively, in postmenopausal women with pharmacologic effects on ER-regulated signaling path- osteoporosis (12). In the Tamoxifen and Raloxifene ways rather than a common chemical structure. As a trial of more than 19,000 postmenopausal women, ral- result, SERMs must be evaluated individually because oxifene was shown to be as effective as tamoxifen in re- each SERM has unique pharmacologic properties that ducing the risk of invasive breast cancer (13). Although determines its clinical potential. An ideal SERM shoul raloxifene has demonstrated efficacy in vertebral frac- prevent bone loss and fractures; reduce the risk of breast ture reduction, it has shown no significant effect on and endometrial cancer (and limit endometrial prolifera- the overall risk of nonvertebral fracture (12,14). Post tion); provide relief of hot flushes and other menopausal hoc analyses of subgroups of women enrolled in the ABE&M todos os direitos reservados. os direitos ABE&M todos symptoms; and not increase the risk of coronary heart MORE trial (15) and those who entered the Continu- © disease, stroke, or deep vein thrombosis (Table 1) (5). ing Outcomes Relevant to Evista trial (16) have shown Copyright Arq Bras Endocrinol Metab. 2010;54/2 201 SERMs and osteoporosis an update a significant reduction in nonvertebral fracture risk at The safety and tolerability profile of lasofoxifene six common sites (clavicle, humerus, wrist, pelvis, hip, seems to be similar to that of raloxifene, although dis- and lower leg) in raloxifene-treated women with severe continuation rates because of adverse events have been baseline vertebral fractures. shown to be more common with lasofoxifene (23). Evi- A statistically significant increase in endometrial dence suggests that lasofoxifene treatment may cause thickness (+0.01 mm) was seen with raloxifene com- increased endometrial thickness compared with place- pared with placebo (+0.27 mm) after 3 years (P < 0.01 bo, although there has been no evidence of an increased vs. placebo) of therapy in the MORE trial, although risk of endometrial hyperplasia or cancer (23). The there was no increase in the risk of endometrial cancer manufacturer of lasofoxifene received a nonapproval let- (17). Venous thromboembolic events occurred in 1.0% ter from the US FDA in September 2005, which cited of women who received raloxifene, compared
Load more

Recommended publications
  • And Active-Controlled Phase 3 Study of Postmenopausal Women with Osteoporosis
    Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130 http://www.biomedcentral.com/1471-2474/11/130 RESEARCH ARTICLE Open Access SafetyResearch article of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis Claus Christiansen*1, Charles H Chesnut III2, Jonathan D Adachi3, Jacques P Brown4, César E Fernandes5, Annie WC Kung6, Santiago Palacios7, Amy B Levine8, Arkadi A Chines8 and Ginger D Constantine8 Abstract Background: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. Methods: Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by adverse event (AE) reporting and routine physical, gynecologic, and breast examination. Results: Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group; rates were similar with bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or placebo.
    [Show full text]
  • Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors
    This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Articles: Cellular/Molecular Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors Kelsey A. Rankin1, Feng Mei1, Kicheol Kim1, Yun-An A. Shen1, Sonia R. Mayoral1, Caroline Desponts2, Daniel S. Lorrain2, Ari J. Green1, Sergio E. Baranzini1, Jonah R. Chan1 and Riley Bove1 1University of California, San Francisco, Weill Institute for Neurosciences, Department of Neurology 2Inception Sciences, San Diego, CA https://doi.org/10.1523/JNEUROSCI.1530-18.2019 Received: 11 June 2018 Revised: 17 January 2019 Accepted: 20 January 2019 Published: 29 January 2019 Author contributions: K.R., Y.-A.A.S., A.J.G., J.R.C., and R.B. designed research; K.R., F.M., K.K., Y.- A.A.S., S.R.M., C.D., D.S.L., and S.B. performed research; K.R. analyzed data; K.R. wrote the first draft of the paper; K.R., J.R.C., and R.B. edited the paper; K.R. wrote the paper; F.M. and J.R.C. contributed unpublished reagents/analytic tools. Conflict of Interest: The authors declare no competing financial interests. We would like to thank the Innovation Program for Remyelination and Repair at the Weill Institute for Neurosciences at the University of California, San Francisco (UCSF). This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS062796, R01NS097428, R01NS095889, R01NS088155], the National Multiple Sclerosis Society [RG5203A4], The Adelson Medical Research Foundation: ANDP (A130141), the Heidrich Family and Friends and the Rachleff Family Endowments.
    [Show full text]
  • Bazedoxifene–Conjugated Estrogens for Treating Endometriosis Endometriosis: Nina S
    Endometriosis: Case Report Bazedoxifene–Conjugated Estrogens Teaching Points for Treating Endometriosis 1. The estrogen receptor (ER) is a definitive down- stream target in endometriosis. As an endometrial ER antagonist, bazedoxifene assures not only block- Valerie A. Flores, MD, ade of estrogen binding, but it also has the ability to Nina S. Stachenfeld, PhD, degrade the receptor. This unique property of baze- and Hugh S. Taylor, MD doxifene blocks estrogen action and makes it an attractive treatment option for endometriosis. 2. Conjugated estrogens paired with bazedoxifene do BACKGROUND: Endometriosis is a gynecologic disorder not require a progestin to block endometrial affecting 6–10% of reproductive-aged women. First-line growth, thus avoiding the side effects associated therapies are progestin-based regimens; however, failure with progestin-based regimens. 08/19/2018 on BhDMf5ePHKbH4TTImqenVGLGjjqParD6K7Nl5tTGGFqgjMmLRmuIlIgbkUbgVXoQ by http://journals.lww.com/greenjournal from Downloaded rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with con- ’ 1 Downloaded that can have a significant effect on patients lives. jugated estrogens is approved for treatment of menopausal Treatment consists of agents that induce atrophy of symptoms, and use in animal studies has demonstrated from regression of endometriotic lesions. As such, it represents endometriotic lesions. There is tremendous need for http://journals.lww.com/greenjournal a potential treatment option for endometriosis. therapies that are effective, have favorable side effect profiles, and can be used long term in women with CASE: A patient with stage III endometriosis referred for symptomatic endometriosis, especially for those not management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated responding to progestin-based regimens.
    [Show full text]
  • Bazedoxifene Plus Conjugated Oestrogens (Duavive®) the East of England Priorities Advisory Committee a Function Of
    PAC - Bazedoxifene plus conjugated oestrogens (Duavive®) The East of England Priorities Advisory Committee A function of FULL EVIDENCE REVIEW Bazedoxifene plus conjugated oestrogens (Duavive®) for post-menopausal symptoms in women with a uterus Recommendations on the use of bazedoxifene plus conjugated oestrogens (Duavive ®) for the treatment of post-menopausal symptoms in women with a uterus Routine commissioning of bazedoxifene plus conjugated oestrogens (Duavive®) for the treatment of post-menopausal symptoms in women with a uterus is currently NOT recommended because: • There is insufficient evidence to quantify the risks and benefits compared to current alternative treatments • There are no long term safety data. • Information on cost effectiveness and cost impact is not currently available. Recommendations will be reviewed in the light of new national guidance, new evidence and information on cost effectiveness. Medicine Bazedoxifene (BZA) plus conjugated oestrogens (CE), Duavive® Proposed sector of prescribing Primary and secondary care Key points/Evidence level Key points • Bazedoxifene acetate is a third generation selective oestrogen receptor modulator (SERM), similar to raloxifene, and has oestrogen-receptor agonist effects on bone, and antagonist effects on uterine and breast tissue. • When a SERM is paired with an oestrogen, it forms a tissue-selective estrogen complex (TSEC); a novel class of therapeutic agents, which achieve an optimal blend of estrogen receptor agonist and antagonist effects for the treatment of menopausal symptoms and prevention of osteoporosis. • Bazedoxifene combined with conjugated estrogens has recently been approved by the Food & Drug Administration (FDA) in the United States (US) for treatment of moderate-to- severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis in women with a uterus as Duavee® and in the European Union (EU), as Duavive®, for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus.
    [Show full text]
  • Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’
    REVIEW CME LEARNING OBJECTIVE: Readers will tailor hormone therapy to the needs of the patient CREDIT HEATHER D. HIRSCH, MD, MS, NCMP ELIM SHIH, MD, NCMP HOLLY L. THACKER, MD, NCMP Assistant Professor, Clinical Internal Medicine, Division Department of Obstetrics and Gynecology, Director of Center for Specialized Women’s Health, of General Internal Medicine, The Ohio State University, Women’s Health Institute, Cleveland Clinic Department of Obstetrics and Gynecology, Women’s Columbus, and Center for Women’s Health, Health Institute, Cleveland Clinic; Professor, Cleveland The Ohio State University Wexner Medical Center, Clinic Lerner College of Medicine of Case Western Upper Arlington, OH Reserve University, Cleveland, OH ERAAs for menopause treatment: Welcome the ‘designer estrogens’ ABSTRACT strogen receptor agonist-antagonists E(ERAAs), previously called selective es- Estrogen receptor agonist-antagonists (ERAAs) selec- trogen receptor modulators (SERMs), have tively inhibit or stimulate estrogen-like action in targeted extended the options for treating the vari- tissues. This review summarizes how ERAAs can be used ous conditions that menopausal women suffer in combination with an estrogen or alone to treat meno- from. These drugs act differently on estrogen pausal symptoms (vasomotor symptoms, genitourinary receptors in different tissues, stimulating re- syndrome of menopause), breast cancer or the risk of ceptors in some tissues but inhibiting them breast cancer, osteopenia, osteoporosis, and other female in others. This allows selective inhibition or midlife concerns. stimulation of estrogen-like action in various target tissues.1 KEY POINTS This article highlights the use of ERAAs Tamoxifen is approved to prevent and treat breast cancer. to treat menopausal vasomotor symptoms It may also have beneficial effects on bone and on car- (eg, hot flashes, night sweats), genitourinary diovascular risk factors, but these are not approved uses.
    [Show full text]
  • Influence of Resveratrol Against Ovariectomy Induced Bone Loss In
    Reproductive Medicine; Endocrinology & Infertility Influence of Resveratrol Against Ovariectomy Induced Bone Loss in Rats: Comparison With Conjugated Equine Estrogen Tibolone and Raloxifene Önder ÇELİK1, Şeyma HASÇALIK1, Mustafa TAMSER2, Yusuf TÜRKÖZ3 Ersoy KEKİLLİ4, Cengiz YAĞMUR4, Mehmet BOZ1 Malatya, Turkey OBJECTIVE: We examined the effect of resveratrol, a phenolic compound found in the skins of most grapes, on bone loss in ovariectomized rats. STUDY DESIGN: A total of 42 young Wistar-albino rats, of which 35 animals were submitted to bilater- al oophorectomy, and 7 rats were submitted to the same surgical incision but without oophorectomy were studied. The rats were assigned to six groups of 7 animals each. For 35 consecutive days the fol- lowing treatments were given: Group 1, sham; group 2, ovariectomized (OVX); group 3, OVX plus resveratrol; group 4, OVX plus conjugated equine estrogen; group 5 OVX plus tibolone; group 6, OVX plus raloxifene. Immediately 40 days after the ovariectomy bone mineral density (BMD) of the lumbar spine and femur by using dual-energy X-ray absorptiometry. The BMD of lumbar region (R1), total femur region (R2) and three neighbor subregions of femur (R3, R4, R5) were drawn. RESULTS: There were no significant difference between OVX and resveratrol groups for R2, R3 and R4 values. Compared with the OVX group, CEE group had lower values for R3 but similar values for R2 and R4. Raloxifene group had significantly higher value than the OVX, resveratrol, CEE and tibolone groups for R2. For R3, raloxifene had significantly higher values than in the ones in resveratrol, CEE and tibolone. For R4 region, raloxifene had significantly higher values than CEE group.
    [Show full text]
  • Menopausal Hormone Therapy
    GYNAECOLOGY ENDOCRINOLOGY Menopausal hormone therapy: where are we now? Menopausal hormone therapy (MHT) is an effective treatment for symptoms associated with menopause, such as hot flushes, night sweats, mood changes, sleep disturbances and changes in sexual function. While the evidence around MHT has changed over the years, there is now international consensus that the benefits of MHT are likely to outweigh the risks for most women aged < 60 years or within ten years of menopause, for whom menopausal symptoms are affecting their quality of life. KEY PRACTICE POINTS: Every woman’s experience of menopause is different, and Among the oestrogen and progestogen formulations perceptions of menopause vary across cultures. Most available, transdermal oestrogen (funded) and micronised women will experience some menopause symptoms, progesterone (not funded) are associated with the lowest however, only some will seek treatment. risk of adverse effects Menopausal hormone therapy (MHT) is likely to offer overall There is no specific recommended duration for MHT. The benefit to women with menopausal symptoms affecting decision to continue treatment should be reviewed on their quality of life if they are aged < 60 years or within ten an annual basis, taking into account any changes in the years of menopause patient’s risk factors, adverse effects and extent of benefit. Adverse outcomes associated with MHT include breast If women primarily seek assistance for urogenital symptoms cancer, stroke and venous thromboembolism (VTE). of menopause, vaginal products are recommended instead However, the risk of these outcomes depends on factors of MHT. This includes moisturisers, lubricants or a vaginal such as the age or time since menopause when MHT oestrogen cream or pessary.
    [Show full text]
  • Effect of Estrogens on Skin Aging and the Potential Role of Selective Estrogen Receptor Modulators
    CLIMACTERIC 2007;10:289–297 Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators S. Verdier-Se´vrain Bio-Hybrid, LLC, West Palm Beach, Florida, USA Key words: SKIN AGING, HORMONE REPLACEMENT THERAPY, TOPICAL ESTROGEN, PHYTOESTROGENS, SELECTIVE ESTROGEN RECEPTOR MODULATORS ABSTRACT Estrogens have a profound influence on skin. The relative hypoestrogenism that accom- panies menopause exacerbates the deleterious effects of both intrinsic and environ- mental aging. Estrogens prevent skin aging. They increase skin thickness and improve skin moisture. Beneficial effects of hormone replacement therapy (HRT) on skin aging have been well documented, but HRT cannot obviously be recommended solely to treat skin aging in menopausal women. Topical estrogen application is highly effective and safe if used by a dermatologist with expertise in endocrinology. The question of whether estrogen alternatives such as phytoestrogens and selective estrogen receptor modulators are effective estrogens for the prevention of skin aging in postmenopausal women remains unanswered. However, preliminary data indicate that such treatment may be of benefit for skin aging treatment. For personal use only. INTRODUCTION There are approximately 40 million postmeno- Intrinsic aging is characterized by smooth, pale, pausal women in the United States, contributing finely wrinkled skin and dryness2. Photoaging is to 17% of the total population1. As the popula- characterized by severe wrinkling and pigmentary tion of older women continues to grow at a rapid changes such as solar lentigo and mottled pig- rate, the challenges of learning more about the mentation3. Estrogens affect several skin functions health-care concerns and priorities of this group of and the estrogen deprivation that accompanies Climacteric Downloaded from informahealthcare.com by University of Washington on 05/23/13 patients become apparent.
    [Show full text]
  • Clinical Update on the Use of Ospemifene in the Treatment of Severe Symptomatic Vulvar and Vaginal Atrophy
    Journal name: International Journal of Women’s Health Article Designation: Review Year: 2016 Volume: 8 International Journal of Women’s Health Dovepress Running head verso: Palacios and Cancelo Running head recto: The use of ospemifene in the treatment of severe symptomatic VVA open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJWH.S110035 Open Access Full Text Article REVIEW Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy Santiago Palacios1 Abstract: The physiological decrease in vaginal estrogens is accountable for the emergence of María Jesús Cancelo2 vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and on quality of life often makes it necessary to initiate treatment. Up until now, the treatments Obstetrics Department, Guadalajara available included vaginal moisturizers and lubricants, local estrogens, and hormonal therapy. University Hospital, University of Alcalá, Spain However, therapeutic options have now been increased with the approval of 60 mg ospemifene, the first nonhormonal oral treatment with an agonist effect on the vaginal epithelium and an endometrial and breast safety profile which makes it unique. This is the first selective estrogen receptor modulator indicated in women with moderate-to-severe vaginal atrophy not eligible For personal use only. for local estrogen treatment. Considering that “local estrogen noneligible women” are those in whom such treatment cannot be administered either because it is contraindicated or due to skill issues, who are averse to the mode and convenience of vaginal products’ administration or to their use on account of potential systemic absorption, or those who demonstrate dissatisfac- tion in terms of efficacy and safety, it is clear that there is a significant unmet medical need in VVA management.
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]
  • Postmenopausal Hormone Therapy Is Accompanied by Elevated Risk for Uterine Prolapse
    Menopause: The Journal of The North American Menopause Society Vol. 26, No. 2, pp. 140-144 DOI: 10.1097/GME.0000000000001173 ß 2018 by The North American Menopause Society Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse Pa¨ivi Rahkola-Soisalo, MD, PhD,1 Hanna Savolainen-Peltonen, MD, PhD,1,2 Mika Gissler, PhD,3,4 Fabian Hoti, PhD,5 Pia Vattulainen, MSc,5 Olavi Ylikorkala, MD, PhD,1 and Tomi S. Mikkola, MD, PhD1,2 Abstract Objective: Receptors for estrogen and progesterone are present in the pelvic floor, and therefore, postmenopausal hormone therapy may affect its function. We compared the former use of estradiol-progestogen postmenopausal hormone therapy in nonhysterectomized women with a uterine prolapse surgery (N ¼ 12,072) and control women (N ¼ 33,704). Methods: The women with a history of uterine prolapse operation were identified from the Finnish National Hospital Discharge Register, and the control women from the Finnish Central Population Register. The use of hormone therapy was traced from the national drug reimbursement register, and the odd ratios with 95% CIs for prolapse were calculated by using the conditional logistic regression analysis. Results: The women with uterine prolapse had used hormone therapy more often than control women (N ¼ 4,127; 34.2% vs N ¼ 9,189; 27.3%; P < 0.005). The use of hormone therapy was accompanied by significant (23%-53%) elevations in the risk for prolapse, being higher with longer exposure. The risk elevations (33%-23%) were comparable between sole norethisteroneacetate-estradiol and sole medroxyprogesteroneacetate-estradiol therapy. The use of estradiol in combination with a levonorgestrel releasing intrauterine device was accompanied by a 52% elevation.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]